Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2004-05-24
2008-08-26
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S506000, C514S529000, C558S260000
Reexamination Certificate
active
07417070
ABSTRACT:
This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:
REFERENCES:
patent: 4306075 (1981-12-01), Aristoff
patent: 4490537 (1984-12-01), Johnson
patent: 4499085 (1985-02-01), Masuda
patent: 5153222 (1992-10-01), Tadepalli et al.
patent: 5234953 (1993-08-01), Crow et al.
patent: 5814301 (1998-09-01), Klopp et al.
patent: 6054486 (2000-04-01), Crow et al.
patent: 6171786 (2001-01-01), Shtil et al.
patent: 6451815 (2002-09-01), Hwang et al.
patent: 6469022 (2002-10-01), Schellens
patent: 2005/0101608 (2005-05-01), Santel
patent: 0 159 784 (1985-10-01), None
patent: WO 99/25357 (1999-05-01), None
Belch et al., “Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1Prodrug, in Patients With Intermittent Claudication,” Circulation, The American Heart Association, Inc., vol. 95, No. 9, May 1997, pp. 2298-2301.
Okuda et al., “Acute Effect of Beraprost Sodium on Lower Limb Circulation in Patients with Non-Insulin-Dependent Diabetes Mellitus-Evaluation by Color Doppler Ultrasonography and Laser Cutaneous Blood Flowmetry,” Prostaglandins, Elsevier, vol. 52, Nov. 1996, pp. 375-384.
Patterson et al., “Acute Hemodynamic Effects of the Prostacyclin Analog 15AU81 in Service Congestive Heart Failure,” The American Journal of Cardiology, vol. 75, Jan. 19, 1995, pp. 26A-33A.
Mohler, “Clinical Manifestations of Claudication,” Up To Date, Inc., Sep. 30, 1996, pp. 1-4.
Mohler, “Medical Management of Claudication,” Up To Date, Inc., Mar. 31, 1997, pp. 1-6.
Neschis et al., “Surgical Indications for the Patient with Limb Threatening Ischemia”, pp. 1-10.
J. C. Lee et al., “Efficient In Situ Esterification of Carboxylic Acids Using Cesium Carbonate,” Organic Preparations and Procedures International, vol. 28, No. 4, Aug. 1996, pp. 480-483.
J. Mann et al., Organic Syntheses, John Wiley & Sons, Inc., vol. 75, 1998, pp. 139-145.
A. Hassner et al., “Direct Room Temperature Esterification of Carboxylic Acids” Tetrahedron Letters, Perganon Press Ltd., vol. 46, 1978, pp. 4475-4478.
Mottola David
Phares Ken
Coppins Janet L.
Foley & Lardner LLP
Saeed Kamal A.
United Therapeutics Corporation
LandOfFree
Compounds and methods for delivery of prostacyclin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for delivery of prostacyclin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for delivery of prostacyclin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4000353